C
1.52
-0.09 (-5.77%)
| Penutupan Terdahulu | 1.61 |
| Buka | 1.62 |
| Jumlah Dagangan | 110,922 |
| Purata Dagangan (3B) | 71,373 |
| Modal Pasaran | 18,998,256 |
| Harga / Jualan (P/S) | 1.20 |
| Harga / Buku (P/B) | 4.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -426.77% |
| EPS Cair (TTM) | -6.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 14.10% |
| Nisbah Semasa (MRQ) | 1.23 |
| Aliran Tunai Operasi (OCF TTM) | -33.58 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.95 M |
| Pulangan Atas Aset (ROA TTM) | -52.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -2,951.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Curis, Inc. | Bercampur | Menurun |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -1.0 |
| Purata | -0.25 |
|
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.64% |
| % Dimiliki oleh Institusi | 44.65% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 Nov 2025 | Pengumuman | Curis to Present at Upcoming 30th Annual SNO Meeting |
| 06 Nov 2025 | Pengumuman | Curis Provides Third Quarter 2025 Business Update |
| 30 Oct 2025 | Pengumuman | Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025 |
| 03 Oct 2025 | Pengumuman | Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |